Kabimycin

Vancomycin is a glycopeptide antibiotic used in the prophylaxis and treatment caused by Gram-positive bacteria.

Kabimycin^TM vial is (500 mg) packaged in 10 ml USP type 1 glass vial along with its pack insert. The stoppers are composed of butyl rubber.

The usual daily intravenous dose is 2 g divided either as 500 mg every 6 hours or 1 g every 12 hours. Each dose should be administered at no more than 10 mg/min or over a period of at least 60 minutes, whichever is longer.

• KABIMYCIN^TM is indicated for initial therapy when Methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly.
• KABIMYCIN^TM is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone and joint infections, lower respiratory tract infections, skin and skin structure infections. 
• KABIMYCIN^TM has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by Streptococcus Viridans- or S. Bovis. For endocarditis caused by enterococci (eg, E. Faecalis), Vancomycin has been reported to be effective only in combination with an aminoglycoside.
• KABIMYCIN^TM has been reported to be effective for the treatment of diphtheroid endocarditis.
•  KABIMYCIN^TM has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. Epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to Vancomycin.
• The parenteral form of Vancomycin may be administered orally for treatment of antibiotic-associated pseudomembranous colitis caused by C. Difficile and for staphylococcal enterocolitis. Parenteral administration of Vancomycin alone is of unproven benefit for these indications.

Each 500 mg vial contains

Vancomycin Hydrochloride IP equivalent to Vancomycin 500mg (5,00,000 IU of Vancomycin activity/Vial).